The start of the year saw Chinese stocks tumbling to five-year lows on growth concerns and deflation deepening to levels unseen since the global financial crisis, prompting comparisons with the 2015 turmoil that forced policymakers into action.
Read More
The start of the year saw Chinese stocks tumbling to five-year lows on growth concerns and deflation deepening to levels unseen since the global financial crisis, prompting comparisons with the 2015 turmoil that forced policymakers into action.
Read More
The Nikkei 225’s stellar rally over the past year caps a recovery that’s made the nation’s equities a top pick among global funds after being overlooked in favor of faster-growing markets like China.
Read More
Sharekhan is bullish on Va Tech Wabag has recommended buy rating on the stock with a target price of Rs 850 in its research report dated February 21, 2024.
Read More
Sharekhan is bullish on Va Tech Wabag has recommended buy rating on the stock with a target price of Rs 850 in its research report dated February 21, 2024.
Read More
With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy#39;s and Lupin — some of the world#39;s largest generic drugmakers — all said…
Read More